Tobacco companies are significantly expanding production of nicotine pouches across the United States as consumer demand for these products rises amid declining cigarette sales. Industry leaders such as Philip Morris International, Reynolds American, Altria, and Swisher are investing over a billion dollars in new manufacturing facilities and job creation from states including Florida, Colorado, Kentucky, North Carolina, Virginia, and South Carolina.

Nicotine pouches are smokeless, tobacco-free products placed in the mouth that deliver nicotine without combustion. Market research forecasts sales of nicotine pouches to surge globally from an estimated $6.9 billion in 2025 to more than $40 billion by 2033. Companies are accelerating production to meet growing demand, with firms like Swedish Match, a Philip Morris International subsidiary, expanding plants in Aurora, Colorado, and Owensboro, Kentucky.

Reynolds American, owned by British American Tobacco, has increased capacity at facilities in Tobaccoville, North Carolina, and Clarksville, Tennessee, creating approximately 1,000 jobs in the past two years. Altria manufactures nicotine pouch brands such as on! and on! PLUS at its Richmond, Virginia, plant, gaining FDA approval for new products under a recent streamlined regulatory program. Meanwhile, Swisher announced a $135 million expansion to its Jacksonville, Florida, factory, aiming to add at least 240 jobs, and Swedish firm WiJo is opening its first North American plant in Lexington, South Carolina.

The U.S. Food and Drug Administration (FDA) recently eased regulations on nicotine pouches and vaping products, a move coinciding with significant political donations from tobacco companies to entities backed by former President Donald Trump. In June, the FDA authorized a Zyn brand product, produced by Swedish Match, to be marketed as having a lower risk for certain cancers and diseases compared to cigarettes. U.S. Health Secretary Robert F. Kennedy Jr. has publicly endorsed nicotine pouches as "probably the safest way to consume nicotine," acknowledging his own use.

Despite the tobacco industry's positioning of nicotine pouches as less harmful alternatives, public health experts raise concerns over their addictive potential and risks—especially for youth. Nicotine dependence can lead to symptoms such as irritability, anxiety, mood changes, and cognitive impairment. Researchers warn that rising nicotine concentrations in pouches, from typical levels of six to eight milligrams up to 15 milligrams per pouch, may increase addiction risks. Critics fear these products could serve as a "gateway" to other harmful tobacco use.

The American Lung Association and the World Health Organization have called for stricter regulations on nicotine pouches amid fears of growing youth uptake. France has gone as far as banning these products, generating tensions with Sweden, where the pouch market originated and is credited by some with lowering smoking rates—a concept referred to as "the Swedish model."

Industry representatives, including Philip Morris International, counter that nicotine pouches target the estimated 25 million U.S. adults who continue to smoke cigarettes, not youth. They highlight the transition toward less harmful nicotine consumption methods as part of harm reduction strategies.

Experts emphasize the need for independent research to clarify the long-term health effects and societal impact of nicotine pouches. Current studies on the products’ safety and toxicity have largely come from industry sources, prompting calls for unbiased scientific evaluation to inform policy and public health responses.